Stockreport

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting [Yahoo! Finance]

Opus Genetics, Inc.  (IRD) 
PDF Opus Genetics, Inc. Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxiciti [Read more]